TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A mere $20 stock of Gilead in 2011 saw a considerable momentum in the years ... as investors could look forward to impressive ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Gilead is a top HIV treatment company ... which pays 3.2% per year in dividends. It's the most expensive stock on this list, trading at a forward P/E of 14. But even that is still incredibly ...

Investors in Gilead Sciences Inc (Symbol ... that would drive a total return (excluding dividends, if any) of 4.19% if the stock gets called away at the December 6th expiration (before broker ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck (NYSE: ...